David Bouchey
Stock Analyst at Aegis Capital
(n/a)
# 4,525
Out of 4,829 analysts
6
Total ratings
n/a
Success rate
-61.2%
Average return
Main Sectors:
Stocks Rated by David Bouchey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SBFM Sunshine Biopharma | Reiterates: Buy | $15 | $1.25 | +1,100.00% | 2 | Dec 5, 2024 | |
| STSS Sharps Technology | Initiates: Buy | $105,600 | $4.73 | +2,232,458.14% | 1 | May 9, 2023 | |
| IINN Inspira Technologies Oxy B.H.N. | Maintains: Buy | $10 → $13 | $0.56 | +2,220.19% | 1 | Jan 25, 2023 | |
| RMTI Rockwell Medical | Downgrades: Outperform | $121 | $1.12 | +10,703.57% | 2 | Oct 19, 2018 |
Sunshine Biopharma
Dec 5, 2024
Reiterates: Buy
Price Target: $15
Current: $1.25
Upside: +1,100.00%
Sharps Technology
May 9, 2023
Initiates: Buy
Price Target: $105,600
Current: $4.73
Upside: +2,232,458.14%
Inspira Technologies Oxy B.H.N.
Jan 25, 2023
Maintains: Buy
Price Target: $10 → $13
Current: $0.56
Upside: +2,220.19%
Rockwell Medical
Oct 19, 2018
Downgrades: Outperform
Price Target: $121
Current: $1.12
Upside: +10,703.57%